1XCG
 
 | | Crystal Structure of Human RhoA in complex with DH/PH fragment of PDZRHOGEF | | Descriptor: | Rho guanine nucleotide exchange factor 11, Transforming protein RhoA | | Authors: | Derewenda, U, Oleksy, A, Stevenson, A.S, Korczynska, J, Dauter, Z, Somlyo, A.P, Otlewski, J, Somlyo, A.V, Derewenda, Z.S. | | Deposit date: | 2004-09-01 | | Release date: | 2004-12-14 | | Last modified: | 2024-02-14 | | Method: | X-RAY DIFFRACTION (2.5 Å) | | Cite: | The crystal structure of RhoA in complex with the DH/PH fragment of PDZRhoGEF, an activator of the Ca(2+) sensitization pathway in smooth muscle
Structure, 12, 2004
|
|
3O0E
 | | Crystal structure of OmpF in complex with colicin peptide OBS1 | | Descriptor: | Colicin-E9, Porin OmpF, octyl beta-D-glucopyranoside | | Authors: | Wojdyla, J.A, Housden, N.G, Korczynska, J, Grishkovskaya, I, Kirkpatrick, N, Brzozowski, A.M, Kleanthous, C. | | Deposit date: | 2010-07-19 | | Release date: | 2010-12-08 | | Last modified: | 2023-09-20 | | Method: | X-RAY DIFFRACTION (3.01 Å) | | Cite: | Directed epitope delivery across the Escherichia coli outer membrane through the porin OmpF.
Proc.Natl.Acad.Sci.USA, 107, 2010
|
|
8OLU
 | |
6QM8
 | | Leishmania tarentolae proteasome 20S subunit apo structure | | Descriptor: | Proteasome alpha1 chain, Proteasome alpha2 chain, Proteasome alpha3 chain, ... | | Authors: | Rowland, P, Goswami, P. | | Deposit date: | 2019-02-01 | | Release date: | 2019-04-17 | | Last modified: | 2024-11-06 | | Method: | ELECTRON MICROSCOPY (3.3 Å) | | Cite: | Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition.
Proc.Natl.Acad.Sci.USA, 116, 2019
|
|
6QM7
 | |
6T6R
 | | Human endoplasmic reticulum aminopeptidase 1 (ERAP1) in complex with (4aR,5S,6R,8S,8aR)-5-(2-(Furan-3-yl)ethyl)-8-hydroxy-5,6,8a-trimethyl-3,4,4a,5,6,7,8,8a-octahydronaphthalene-1-carboxylic acid | | Descriptor: | (4~{a}~{R},5~{S},6~{R},8~{S},8~{a}~{R})-5-[2-(furan-3-yl)ethyl]-5,6,8~{a}-trimethyl-8-oxidanyl-3,4,4~{a},6,7,8-hexahydronaphthalene-1-carboxylic acid, 1,2-ETHANEDIOL, D-MALATE, ... | | Authors: | Rowland, P. | | Deposit date: | 2019-10-18 | | Release date: | 2020-03-18 | | Last modified: | 2024-10-16 | | Method: | X-RAY DIFFRACTION (1.67 Å) | | Cite: | Targeting the Regulatory Site of ER Aminopeptidase 1 Leads to the Discovery of a Natural Product Modulator of Antigen Presentation.
J.Med.Chem., 63, 2020
|
|
9GJS
 | | ERAP1 in complex with 1-[2-(6-bromo-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-4-yl)acetamido]-4,4-difluorocyclohexane-1-carboxylic acid | | Descriptor: | 1,2-ETHANEDIOL, 1-[2-(6-bromanyl-3-oxidanylidene-1,4-benzoxazin-4-yl)ethanoylamino]-4,4-bis(fluoranyl)cyclohexane-1-carboxylic acid, Endoplasmic reticulum aminopeptidase 1, ... | | Authors: | Rowland, P. | | Deposit date: | 2024-08-22 | | Release date: | 2025-01-22 | | Method: | X-RAY DIFFRACTION (1.351 Å) | | Cite: | Optimization of Potent and Selective Cyclohexyl Acid ERAP1 Inhibitors Using Structure- and Property-Based Drug Design.
Acs Med.Chem.Lett., 15, 2024
|
|
9GK6
 | | ERAP1 in complex with 1-[2-(6-chloro-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-4-yl)acetamido]cyclohexane-1-carboxylic acid | | Descriptor: | 1,2-ETHANEDIOL, 1-[2-(6-chloranyl-3-oxidanylidene-1,4-benzothiazin-4-yl)ethanoylamino]cyclohexane-1-carboxylic acid, D-MALATE, ... | | Authors: | Convery, M, Rowland, P. | | Deposit date: | 2024-08-23 | | Release date: | 2025-01-22 | | Method: | X-RAY DIFFRACTION (1.327 Å) | | Cite: | Optimization of Potent and Selective Cyclohexyl Acid ERAP1 Inhibitors Using Structure- and Property-Based Drug Design.
Acs Med.Chem.Lett., 15, 2024
|
|
9GKE
 | | ERAP1 in complex with 1-[2-(2-oxo-5-phenyl-2,3-dihydro-1,3-benzothiazol-3-yl)acetamido]cyclohexane-1-carboxylic acid | | Descriptor: | 1,2-ETHANEDIOL, 1-[2-(2-oxidanylidene-5-phenyl-1,3-benzothiazol-3-yl)ethanoylamino]cyclohexane-1-carboxylic acid, Endoplasmic reticulum aminopeptidase 1, ... | | Authors: | Chung, C. | | Deposit date: | 2024-08-23 | | Release date: | 2025-01-22 | | Method: | X-RAY DIFFRACTION (1.367 Å) | | Cite: | Optimization of Potent and Selective Cyclohexyl Acid ERAP1 Inhibitors Using Structure- and Property-Based Drug Design.
Acs Med.Chem.Lett., 15, 2024
|
|
9GJN
 | | ERAP1 in complex with 1-[2-(3-oxo-3,4-dihydro-2H-1,4-benzothiazin-4-yl)acetamido]cyclohexane-1-carboxylic acid | | Descriptor: | 1,2-ETHANEDIOL, 1-[2-(3-oxidanylidene-1,4-benzothiazin-4-yl)ethanoylamino]cyclohexane-1-carboxylic acid, 2-[3-(2-HYDROXY-1,1-DIHYDROXYMETHYL-ETHYLAMINO)-PROPYLAMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL, ... | | Authors: | Rowland, P. | | Deposit date: | 2024-08-22 | | Release date: | 2025-01-22 | | Method: | X-RAY DIFFRACTION (1.717 Å) | | Cite: | Optimization of Potent and Selective Cyclohexyl Acid ERAP1 Inhibitors Using Structure- and Property-Based Drug Design.
Acs Med.Chem.Lett., 15, 2024
|
|
5FV2
 | | Crystal structure of hVEGF in complex with VH domain antibody | | Descriptor: | VASCULAR ENDOTHELIAL GROWTH FACTOR, VH DOMAIN ANTIBODY | | Authors: | Chung, C, Batuwangala, T. | | Deposit date: | 2016-02-02 | | Release date: | 2016-02-17 | | Last modified: | 2024-11-20 | | Method: | X-RAY DIFFRACTION (3.45 Å) | | Cite: | Novel Interaction Mechanism of a Domain Antibody Based Inhibitor of Human Vascular Endothelial Growth Factor with Greater Potency Than Ranibizumab and Bevacizumab and Improved Capacity Over Aflibercept.
J.Biol.Chem., 291, 2016
|
|
5FV1
 | | Crystal structure of hVEGF in complex with VK domain antibody | | Descriptor: | VASCULAR ENDOTHELIAL GROWTH FACTOR A, VK DOMAIN ANTIBODY | | Authors: | Chung, C, Walker, A. | | Deposit date: | 2016-02-02 | | Release date: | 2016-02-17 | | Last modified: | 2024-11-13 | | Method: | X-RAY DIFFRACTION (2.7 Å) | | Cite: | Novel Interaction Mechanism of a Domain Antibody Based Inhibitor of Human Vascular Endothelial Growth Factor with Greater Potency Than Ranibizumab and Bevacizumab and Improved Capacity Over Aflibercept.
J.Biol.Chem., 291, 2016
|
|
